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Abstract 
Deep Learning can significantly benefit cancer proteomics and genomics.  In this study, 
we attempt to determine a set of critical proteins that are associated with the FLT3-ITD 
mutation in newly-diagnosed acute myeloid leukemia patients.  A Deep Learning 
network consisting of autoencoders forming a hierarchical model from which high-level 
features are extracted without labeled training data. Dimensional reduction reduced the 
number of critical proteins from 231 to 20. Deep Learning found an excellent correlation 
between FLT3-ITD mutation with the levels of these 20 critical proteins (accuracy 97%, 
sensitivity 90%, specificity 100%). Our Deep Learning network could hone in on 20 
proteins with the strongest association with FLT3-ITD.  The results of this study allow a 
novel approach to determine critical protein pathways in the FLT3-ITD mutation, and 
provide proof-of-concept for an accurate approach to model big data in cancer proteomics 
and genomics. 
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INTRODUCTION 
Acute myeloid leukemia (AML) is a neoplasm of the bone marrow which is caused by 
mutations in the myeloid stem cells leading to the formation of aberrant myeloblasts. 
The highly proliferative cancer cells impede the formation of normal blood cells, 
eventually causing death if patients are left untreated.  There are about 19,000 new cases 
and 10,000 deaths from this disease in 2016. As only a quarter of the patients diagnosed 
with AML survive beyond 5 years, there is an urgent need to find better treatments for 
this type of leukemia. AML includes many subtypes that share a common clinical 
presentation despite arising from diverse mutations and genetic events.  A variety of 
technologies targeting the gene, mRNA, microRNA and protein level have helped 
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predicting the prognosis of AML patients. Interestingly, most AMLs only have only a 
few gene mutations, but prognosis of AML patients is quite varied. A possible 
explanation for this diversity is differences in protein signaling. The genetic aberrations 
and mutations of myeloid leukemic cells often cause a profound impact on the cellular 
protein networks.  Proteomics include a vast collection of techniques allowing for 
analysis of proteins at the cellular level. Therefore, proteomics could be an ideal tool for 
predicting responses as well as for monitoring targeted therapy. Much work remains to 
determine a critical set of proteins involved in any particular mutation before 
pathogenesis can be elucidated.  
 
Our study focuses on one of the most clinically significant mutations in AML, the FMS-
Like Tyrosine Kinase 3 (FLT3) gene mutation. The FLT3 protein is a member of the 
class III receptor-tyrosine kinase (RTK) family and it is encoded by a gene located on 
chromosome 13q12 and. FLT3 shares a high degree of structural homology with the KIT, 
FMS and PDGFR receptors1. FLT3 plays a critical role in normal growth and 
differentiation of precursor cells in bone marrow. Upon binding of ligand, the FLT3 
receptor dimerizes at the plasma membrane, leading to autophosphorylation and 
activation of several downstream effector signaling cascades. These cascades include the 
RAS/MEK, PI3K/AKT/mTOR, and STAT-5 pathways, all of which are important in cell 
cycle progression, inhibition of apoptosis, and activation of differentiation. Mutant FLT3 
is expressed at higher levels, and demonstrates ligand-independence, causing constitutive 
autophosphorylation and activation of downstream signaling. The most common type of 
FLT3 mutations is internal tandem duplication (ITD) mutation. It activates signal 
transduction pathways in the juxta-membranous region, which are typically not activated 
by ligand-stimulated wild-type FLT3 1,2. ITD mutation occurs in about 23% of patients 
with de-novo AML. While AML patients with FLT3-ITD have potential to achieve initial 
complete remission as those with wild-type FLT3, they have a higher relapse rate and 
poorer response to salvage therapy. At the presence, inhibitors of FLT3 have not been 
shown to improve overall survival. 
 
DREAM, which stands for Dialogue for Reverse Engineering Assessment and Methods, 
is a platform for collaborative community studies that focus on developing computational 
tools to solve biomedical problems3. The DREAM Challenges crowd-source non-profit 
studies which are supported by contributors from universities, computer technology 
companies like IBM Research, non-profit organizations like Sage Bionetworks, 
biotechnology and pharmaceutical companies. DREAM and Sage Bionetworks offer 
open data access to participants who wish to solve complex problems. Since the first 
DREAM Challenge in 2006, their participants have presented numerous findings in 
leading biomedical journals.  DREAM challenges leverage the wisdom of the crowd to 
develop innovative computational models, and making these methods available to the 
public.  All insight gained during a challenge is stored on their Synapse web site4 to be 
shared with the research community. The DREAM Challenges offer a wonderful source 
of various types of cancer for scientific research. The DREAM 9 Challenge (AML 
Outcome Prediction Challenge), hosted by Rice University, Houston, Texas, provides a 
unique source of data on AML patients which we utilized in this study. 
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The correlation between protein expressions and mutations in cancer cells plays an 
important role in clinical applications5. The protein expression profiles from samples of 
cancer patients may be compared to those from normal samples, allowing for studying 
the disease pathology. Machine learning classification techniques have been used to 
classify tissue samples into mutated type versus normal type. However, due to the high 
dimensions of protein expression data (i.e. the high number of protein in each sample) 
and the availability of only a relatively small number of samples for a given mutation, the 
analysis presents significant challenges to how to process such data. The first challenge is 
to reduce the number of proteins in such a way that ensures sufficient information to 
perform accurate classification, but at the same time eliminates superfluous information 
(background noise). Several solutions have been made available to address the high 
dimension problem, most of which perform feature space reduction by constructing key 
features either manually or in supervised ways. This feature space reduction, however, 
leads to methods that are typically not scalable. The second challenge involves small 
sample sets (i.e. a small number of training examples) making the problem difficult to 
solve and increasing the risk of over-fitting. We propose, in this paper, the use of Deep 
Learning methods based on unsupervised feature extraction to address the two challenges 
described above. 
 
Most successful Deep Learning methods involve artificial neural networks, a family of 
models inspired by biological neural networks (the central nervous system, particularly 
the brain). In such an artificial neural network, artificial nodes (known as "neurons") are 
connected together to form a network mimicking a biological neural network. Warren 
McCulloch and Walter Pitts created a computational model for neural networks based on 
an algorithm called threshold logic6 in 1943. Neural networks had not shown superior 
performance compared to other machine learning methods until the introduction of Deep 
Learning in 2006. The core concept of Deep Learning involves learning the hierarchical 
structure of data by initially extracting simple low-level features, which are progressively 
used to build up more complex features, capturing the underlying features of the data. A 
simple example is demonstrated for a facial recognition task, in which each pixel of the 
image may be represented at the input layer. The input data are compressed in the hidden 
layer into features such as “large eye” or “small nose.” In other words, the input data of 
the face can be described using learned features with less information than is given in the 
original image. Such compressed data can then be used to represent the input data at the 
output layer, allowing the facial image to be reconstructed entirely from the learned 
features.  We use stacked autoencoders which form a deep network capable of achieving 
unsupervised learning, a type of machine-learning algorithm which draws inferences 
from the input data and does not use labeled training examples.  In contrast to previous 
methods of conventional neural network where data must be strictly categorized to 
provide the appropriate label for supervised learning, the unlabeled data in Deep 
Learning can be used in unsupervised training phase.  The resulting features from all 
training sets are then used as a basis for the construction of the classifier.  
 
In this study, we attempt to use Deep Learning which incorporates unsupervised feature 
training to find correlation between the FLT3-ITD mutation and levels of a set of critical 
proteins. To the best of our knowledge, unsupervised feature learning methods have not 
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been applied to protein expression analysis. Our study also involves the use of 
conventional neural network, which we will compare to the performance of the Deep 
Learning network against.  
 
MATERIALS AND METHODS 
Materials: 
The data in this study were obtained from the DREAM 9 Challenge that includes 
patients’ demographics, cytogenetics, selected gene mutation status, and proteomic data 
for 191 patients diagnosed with AML3. The data had been de-identified to exclude all 
personal information prior to release on the DREAM 9 Challenge web site. Patients 
were all newly-diagnosed and had not been treated before blood sample drawing. 
Proteomics data include serum level of 231 proteins obtained by reverse phase protein 
array (RPPA) method.   The testing procedure has been described in details elsewhere7 
and is illustrated in Fig. 1. To exclude any factors that may confound the analysis in this 
study, we only included patients with normal cytogenetics, and FLT3-ITD (if present) is 
the sole mutation. With these restrictions, the number of cases in this study is reduced to 
62 (normal cytogenetics, positive or negative for FLT3-ITD, no other mutations found). 
 
 
 
Fig. 1 The Reverse Phase Protein Array (RPPA) Method to Measure Protein Levels7  
Image Source3 
 
      Notes: 
     - Cells were standardized at a concentration of 10,000 cells per microliter 
     - Samples came from either blood or bone marrow. No statistical difference was  
       determined for protein expression from blood vs. bone marrow  
 
 
Methods: 
Our main analysis method is a Deep Learning neural network with stacked (multi-
layered) auto-encoder. Training will be mostly based on unsupervised feature learning 
which has been used successfully for image and audio recognition8,9. Our Deep Learning 
neural network was designed with the R language. R is a programming language  
for statistical computing and graphics supported by the R Foundation for Statistical 
Computing10. R was derived from the S language which was originally developed at Bell 
5 
 
Laboratories by John Chambers and colleagues. R's popularity has increased substantially 
in recent years with advances in machine learning11. The source code for the R software 
environment is written primarily in Java, C, FORTRAN, and also R itself.  R is freely 
available under the GNU General Public License, and pre-compiled binary versions are 
provided for various operating systems including UNIX, Windows and MacOS. In this 
study, we use many Deep Learning functions obtained from various R packages which 
are available from the Comprehensive R Archive Network12.  To compare the 
performance of our Deep Learning neural network to that of a conventional neural 
network, we will also include in this study a conventional neural network (EasyNN, 
Neural Planner Software, Cheshire, England), 
 
 
Fig 2. A Conventional Neural Network with only Supervised Training Phase 
Image Source50 
 
Legends:   Step (1): Input of training attributes with feed forward  
                  Step (2): Actual output is compared to desired output 
                  Step (3): Connecting weights are adjusted to minimize error 
 
 
 
The conventional neural network, illustrated in Fig. 2, uses the well-established 
supervised training with back-propagation and sigmoid activation function13. The 
learning strategy for a conventional neural network starts with randomly initializing the 
weights of the network, followed by supervised backpropagation via gradient descent. 
This method has been shown to find suboptimal solutions for networks with multiple 
hidden layers14.  It has been suggested that with randomly initialized weights, the 
gradient-based training of supervised neural networks may get stuck in local minima or 
plateaus15 and that it is difficult to find a solution with more layers. The stacked 
autoencoder neural network, illustrated in Fig. 3, incorporates two training phases: pre-
training with unsupervised learning method, and fine-tuning which is similar to the 
supervised back-propagation in conventional neural network16,17. During pre-training 
phase, the output from one layer is subsequently used as the input for the next output 
layer. The output from each layer in essence represents an approximation of the input 
data constructed from a limited number of features represented by the hidden units of the  
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Fig 3. A Deep Learning Neural Network (Stacked Autoencoder Network) with Unsupervised Training in 
Pre-training Phase and Supervised Training in the Fine-tuning phase 
Image Source51 
 
   Legends:  
      dA1, dA2, dA3: autoencoders stacked in sequence 
      W1, W2, W3, W4: functions to extract key features from training attributes 
 
 
network. The stacked autoencoder is constructed by multiple layers in the neural network 
(i.e. input layer, hidden layers, and output layer). The sigmoid function is used as 
activation function in hidden layers. In fine-tuning phase, the back-propagation method 
minimizes the error with an additional sparsity penalty18. The features learned in the pre-
training phase are subsequently used with a set of labeled data for specific mutation status 
(positive or negative) to train a classifier. A classifier can be defined as a function that 
receives values of various features from training examples (protein levels as independent 
variables) and provides an output which predicts the category that each training example 
belongs to (mutation status as dependent variable)19. For the fine-tuning phase, we used 
linear function for the classifier.  
 
We first performed training for both the conventional and the Deep Learning neural 
networks with the original training set including all 231 proteins and compared the two 
networks in terms of accuracy in predicting FLT3-ITD mutation status in the cross-
validation sets. High dimensionality of protein expression data is likely to introduce 
background noise in addition to relevant proteins in the training set. We addressed this 
dimensionality problem in protein expression data by reducing the dimensionality of the 
feature space to the most relevant number of proteins based on the ranking of the proteins 
in training. The ranking of each protein is based on the sum of the absolute weights of the 
connections from the input node to all the nodes in the first hidden layer20.  The 
performance of the two neural networks in terms of accuracy in predicting mutation 
status using this new scaled-down protein set was compared. A cross-validation method 
was used to obtain comprehensive validation results due to the small number of 62 
samples. In this validation method, a small subset of data (10 out of 62) is excluded each 
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time for training; the resultant trained network will be used to predict the mutation status 
for each case in the excluded subset. The process will be repeated until all 62 cases in the 
data set have been validated. The overall accuracy of each neural network is the mean of 
those for all the validated subsets. 
 
RESULTS 
The initial use of the full attribute set of 231 proteins yields 72% accuracy for the 
conventional network. The Deep Learning network performs better at 81% accuracy. 
Using the top 20 proteins ranked in this initial trial (Table 1), the conventional network 
achieves a better accuracy of 87%. The best accuracy is obtained by the Deep Learning 
network with 20 proteins at 97%. This remarkable accuracy corresponds to a sensitivity 
of 90% and a specificity of 100% for predicting positive FLT3-ITD status of an AML 
case using the level of 20 proteins.  Using a smaller or larger number of proteins than 20 
do not yield better accuracy (data not shown) indicating that 20 is the optimal number of 
proteins for this study. It appears that fewer than 20 proteins contain insufficient data for 
prediction. Conversely, more than 20 proteins would introduce background noise, 
compromising accuracy. Scaling down the number of proteins in training significantly 
reduces the number of data points for analysis from 14,322 (for 231 proteins and 62 
cases) down to 1,240 (for 20 proteins and 62 cases). The accuracy in predicting FLT3-
ITD status with different protein data sets by conventional neural networks vs. Deep 
Learning networks is summarized in Table 2. The compression of original features 
through training is illustrated in Fig. 4. The original features show a spread-out pattern 
whereas the extracted features are more compact, indicating a higher level of 
representation. 
 
During the course of network training, we have tried various configurations for the two 
neural networks to achieve optimal accuracy and have the following important 
observations:  
(a) The conventional neural net performs best with only one hidden layer, a fact well 
known with this type of neural network which relies strictly on supervised learning and 
multiple hidden layers present difficulty in training, often leading to no convergence in 
training (no learning achieved). For this reason, we use only one hidden layer for the 
conventional neural network in this study. Despite this limitation, 2 validation subsets 
(subsets 1 and 5) still show no convergence with 231 proteins. 
(b) The Deep Learning network performs very well with 3 hidden layers consisting of 20, 
15, 10 nodes, respectively for the 20-protein set. However, suboptimal results are 
obtained with the 231-protein set. For this reason, we use only 2 hidden layers which 
contain 10 and 5 nodes, respectively for 231 proteins to achieve better performance. 
 
The use of machine learning algorithms frequently involves careful tuning of learning 
parameters and other model parameters. This tuning often requires experience, and 
sometimes brute-force search21. The parameters for the optimal configurations used in 
our neural networks, obtained through trial and error, are as follows: 
- The conventional neural network20: Learning rate: 0.6, Momentum: 0.8 
- The Deep Learning network22: Learning rate: 0.5, Momentum: 0.5 
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Table 1. The List of the 20 Top-Ranking Proteins Used in Training 
 
Legends: 
-Column: position of the protein in the dataset 
-Input Name: name of protein 
-Importance: the sum of the absolute weights of the connections from the input node to   
  all the nodes in the first hidden layer20.   
 
 
 
Table 2. Accuracy in Predicting Positive FLT3-ITD Status with Different Protein Data Sets by 
Conventional Neural Networks vs. Deep Learning Networks 
Neural Networks 231 Protein Data Set 20 Protein Data Set 
Conventional  Validation Set No. Accuracy Validation Set No. Accuracy 
1 NC* 1 80% 
2 80% 2 80% 
3 60% 3 90% 
4 60% 4 90% 
5 NC* 5 90% 
6 90% 6 90% 
7 70% 7 90% 
Mean= 72% Mean= 87% ** 
Deep Learning 1 80% 1 100% 
2 90% 2 100% 
3 70% 3 80% 
4 80% 4 100% 
5 80% 5 100% 
6 90% 6 100% 
7 80% 7 100% 
Mean= 81% Mean= 97% *** 
Legends: 
*NC: no convergence in learning 
** corresponding to sensitivity of 75%, and specificity of 93% 
*** corresponding to sensitivity of 90%, and specificity of 100% 
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Fig. 4 Graphic Display Representing the Original Features (Left) and the more compact Extracted Features 
(Right) Obtained Through Pre-Training in Deep Learning 
 
 
 
 
 
DISCUSSION 
Deep Learning algorithms are new and innovative tools of research in machine learning 
to extract complex data representations at high levels of abstraction. In fact, Deep 
Learning has been cited as one of the 10 breakthrough technologies in 2013 by MIT 
Technology Review23. The most important contribution of Deep Learning algorithms is 
to develop a hierarchical architecture of data, where higher-level features are defined in 
terms of lower-level features. The hierarchical learning architecture of Deep Learning 
algorithms is motivated by the biological structure of the primary sensorial areas of the 
neocortex in the human brain, which automatically extracts abstract features from the 
underlying data24-26. Deep Learning algorithms rely on large amounts of unsupervised 
data, and typically learn data representations in a greedy layer-wise fashion27,28. Studies 
have shown that data representations obtained from stacking up nonlinear feature 
extractors (as in stacked autoencoders used in our study) often yield better machine 
classification results29-31. 
 
Deep Learning applications have produced outstanding results in different areas, 
including speech recognition32-36, computer vision27,28,37, and natural language 
processing38-40. A recent challenge hosted by the International Symposium on Biomedical 
Imaging (ISBI) in 2016 lead to a successful deep learning system for automated detection 
of metastatic cancer from whole slide images of sentinel lymph nodes41. Data-intensive 
technologies in proteomics and genomics as well as improved computational and data 
storage resources have contributed to Big Data science 42. Technology-based companies 
such as Microsoft, Google, Yahoo, and Amazon have maintained databases that are 
measured in exabyte proportions or larger. Various private and public organizations have 
invested in Big Data Analytics to address their needs in business and research 43, making 
this an exciting area of data science research.  
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In the present study, we used Deep Learning for proteomics analysis in acute myeloid 
leukemia (AML). Specifically, we determined a set of 20 critical proteins that are 
associated with FLT3-ITD mutation out of 231 proteins available in newly-diagnosed 
AML patients.  We implemented a Deep Learning network consisting of autoencoders 
that are stacked to form hierarchical deep models from which high-level features are 
compressed, organized, and extracted, without labeled training data. Dimensional 
reduction was initially performed to reduce the number of critical proteins from 231 to 
20. We then showed how Deep Learning, which incorporates unsupervised feature 
training, can be used to find excellent correlation between positive FLT3-ITD mutation 
status with levels of these 20 proteins (an accuracy of 97%, sensitivity of 90%, and 
specificity of 100%).  Our study also showed that the Deep Learning network 
outperforms the conventional neural network in this task (with lower accuracy of 86.7%, 
sensitivity of 75%, and specificity of 93%). Note that our objective is not to determine 
the set of critical proteins to detect FLT3-ITD mutation since existing testing technology 
with polymerase chain reaction (PCR) is much better for this purpose. Instead our goal is 
to determine what key proteins are involved in FLT3-ITD mutation. 
 
CONCLUSION 
The results of this study yield a critical dataset of 20 key proteins in FLT3-ITD mutation 
for further potential research to determine important protein pathways for this mutation in 
AML, to explore pathogenesis involving the mutation, to monitor chemotherapy 
response, and to design personalized treatment. To the best of our knowledge, Deep 
Learning with unsupervised feature learning methods has not been applied to protein 
expression analysis in AML. While the amount of data used here is relatively modest, this 
study provides a proof-of-concept for using Deep Learning neural network as a more 
accurate approach for modeling big data in cancer genomics and proteomics.  
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